US 11,814,431 B2
B7-H4 antibodies and methods of use thereof
Charles Kaplan, San Francisco, CA (US); Derrick Houser, San Francisco, CA (US); Luis Borges, San Mateo, CA (US); Gloria Brattich, San Francisco, CA (US); David Bellovin, San Jose, CA (US); Felicia Kemp, San Jose, CA (US); Majid Ghoddusi, Walnut Creek, CA (US); Nels P. Nielson, Lebanon, NH (US); Kathy Miller, San Francisco, CA (US); and Maike Schmidt, San Francisco, CA (US)
Assigned to FIVE PRIME THERAPEUTICS, INC., South San Francisco, CA (US)
Filed by Five Prime Therapeutics, Inc., South San Francisco, CA (US)
Filed on Mar. 10, 2020, as Appl. No. 16/814,627.
Application 16/814,627 is a continuation of application No. 16/111,064, filed on Aug. 23, 2018, granted, now 11,306,144.
Claims priority of provisional application 62/656,789, filed on Apr. 12, 2018.
Claims priority of provisional application 62/607,810, filed on Dec. 19, 2017.
Claims priority of provisional application 62/579,774, filed on Oct. 31, 2017.
Claims priority of provisional application 62/550,173, filed on Aug. 25, 2017.
Prior Publication US 2020/0255528 A1, Aug. 13, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); G01N 33/53 (2006.01); A61P 35/00 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2827 (2013.01) [A61P 35/00 (2018.01); C07K 16/2818 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/40 (2013.01); C07K 2317/41 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/74 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 48 Claims
 
1. An isolated IgG antibody or antigen-binding fragment thereof that specifically binds to human B7-H4, comprising a heavy chain variable region (VH) complementarity determining region (CDR) 1, a VH CDR2, a VH CDR3 and a light chain variable region (VL) CDR1, a VL CDR2, and a VL CDR3 wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprise amino acid sequences selected from the group consisting of:
(a) SEQ ID NOs:458-463, respectively;
(b) SEQ ID NOs:5-10, respectively;
(c) SEQ ID NOs:15-20, respectively;
(d) SEQ ID NOs:25-30, respectively;
(e) SEQ ID NOs:35-40, respectively; and
(f) SEQ ID NOs:45-50, respectively.